Literature DB >> 28108375

The role of pattern recognition receptors in lung sarcoidosis.

Esmaeil Mortaz1, Ian M Adcock2, Atefhe Abedini3, Arda Kiani4, Mehdi Kazempour-Dizaji5, Masoud Movassaghi6, Johan Garssen7.   

Abstract

Sarcoidosis is a granulomatous disorder of unknown etiology. Infection, genetic factors, autoimmunity and an aberrant innate immune system have been explored as potential causes of sarcoidosis. The etiology of sarcoidosis remains unknown, and it is thought that it might be caused by an infectious agent in a genetically predisposed, susceptible host. Inflammation results from recognition of evolutionarily conserved structures of pathogens (Pathogen-associated molecular patterns, PAMPs) and/or from reaction to tissue damage associated patterns (DAMPs) through recognition by a limited number of germ line-encoded pattern recognition receptors (PRRs). Due to the similar clinical and histopathological picture of sarcoidosis and tuberculosis, Mycobacterium tuberculosis antigens such early secreted antigen (ESAT-6), heat shock proteins (Mtb-HSP), catalase-peroxidase (katG) enzyme and superoxide dismutase A peptide (sodA) have been often considered as factors in the etiopathogenesis of sarcoidosis. Potential non-TB-associated PAMPs include lipopolysaccharide (LPS) from the outer membrane of Gram-negative bacteria, peptidoglycan, lipoteichoic acid, bacterial DNA, viral DNA/RNA, chitin, flagellin, leucine-rich repeats (LRR), mannans in the yeast cell wall, and microbial HSPs. Furthermore, exogenous non-organic antigens such as metals, silica, pigments with/without aluminum in tattoos, pesticides, and pollen have been evoked as potential causes of sarcoidosis. Exposure of the airways to diverse infectious and non-infectious agents may be important in the pathogenesis of sarcoidosis. The current review provides and update on the role of PPRs and DAMPs in the pathogenesis of sarcoidsis.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Mycobacteria; Pattern recognition receptors; Propionibacterium; Sarcoidosis; TLR2; TLR4

Mesh:

Substances:

Year:  2017        PMID: 28108375     DOI: 10.1016/j.ejphar.2017.01.020

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

Review 1.  Toll-like receptor 3 (TLR3) regulation mechanisms and roles in antiviral innate immune responses.

Authors:  Yujuan Chen; Junhong Lin; Yao Zhao; Xianping Ma; Huashan Yi
Journal:  J Zhejiang Univ Sci B       Date:  2021-08-15       Impact factor: 3.066

2.  Oridonin protects LPS-induced acute lung injury by modulating Nrf2-mediated oxidative stress and Nrf2-independent NLRP3 and NF-κB pathways.

Authors:  Huahong Yang; Hongming Lv; Haijun Li; Xinxin Ci; Liping Peng
Journal:  Cell Commun Signal       Date:  2019-06-11       Impact factor: 5.712

3.  Single nucleotide polymorphisms of Toll-like receptor-4 and of autophagy-related gene 16 like-1 gene for predisposition of premature delivery: A prospective study.

Authors:  Christakis Liassides; Antonios Papadopoulos; Charalampos Siristatidis; Georgia Damoraki; Aspasia Liassidou; Charalampos Chrelias; Dimitrios Kassanos; Evangelos J Giamarellos-Bourboulis
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.889

Review 4.  Refractory Sarcoidosis: A Review.

Authors:  Thomas El Jammal; Yvan Jamilloux; Mathieu Gerfaud-Valentin; Dominique Valeyre; Pascal Sève
Journal:  Ther Clin Risk Manag       Date:  2020-04-17       Impact factor: 2.423

5.  Exome Sequencing Reveals Genetic Variability and Identifies Chronic Prognostic Loci in Chinese Sarcoidosis Patients.

Authors:  Qian Zhang; Hui Huang; Meijun Zhang; Chuling Fang; Na Wang; Xiaoyan Jing; Jian Guo; Wei Sun; Xiaoyu Yang; Zuojun Xu
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

6.  Oridonin attenuates the release of pro-inflammatory cytokines in lipopolysaccharide-induced RAW264.7 cells and acute lung injury.

Authors:  Gan Zhao; Tao Zhang; Xiaofei Ma; Kangfeng Jiang; Haichong Wu; Changwei Qiu; Mengyao Guo; Ganzhen Deng
Journal:  Oncotarget       Date:  2017-07-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.